Cognition Therapeutics Stock Forum

$Cognition Therapeutics(CGTX.US)$
NEWS
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
Cognition Therapeutics (NASDAQ: CGTX) released the eighth episode of its Conversations video podcast titled “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease.” This episode explores how beta amyloid (Aβ) oligomers lead to synaptic dysfunction and cognitive decline. The podcast discusses recent researc...

$Cognition Therapeutics(CGTX.US)$ Cognition Therapeutics To Be Issued US Patent Number 11,981,636 Titled "COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES (INCLUDING ALZHEIMER'S DISEASE AND COGNITIVE DECLINE)"

$Cognition Therapeutics(CGTX.US)$
NEWS
Cognition Therapeutics To Be Issued US Patent Number 11,981,636 Titled "COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES (INCLUDING ALZHEIMER'S DISEASE AND COGNITIVE DECLINE)"

$Cognition Therapeutics(CGTX.US)$ Cognition Therapeutics Inc: Top-Line Results Are Expected in Second Half of 2024 After Last Participants Have Completed Six Months of Treatment

$Cognition Therapeutics(CGTX.US)$
NEWS
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies

$Cognition Therapeutics(CGTX.US)$ Cognition Therapeutics Has Received A Notice Of Allowance For Its U.S. Patent Application 17/537,110 Titled "Compositions For Treating Neurodegenerative Diseases (Including Alzheimer's Disease And Cognitive Decline)"

$Cognition Therapeutics(CGTX.US)$ Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer's and Parkinson's Diseases
Benzinga· just